Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancers

NCT03471078 is registered in ClinicalTrials.gov with Sobi, Inc. as lead sponsor.

NCT NCT03471078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03471078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancers
Lead sponsor
Sobi, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 12, 2018
Completion date
January 31, 2023
Enrollment
122 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced thrombocytopenia